Search

Search
- Search

Harnessing Microbial Recognition and Host Defense Responses To Fight Cancer

Manhattan BioSolutions is an emerging biotech company focused on the development of biologic therapies that target microbial recognition and host-defense pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues

In the News

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

Grant Award from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

Manhattan BioSolutions Announces Positive Preclinical Data Validating its Novel Synthetic Microbial Therapeutic Platform

Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

Manhattan BioSolutions Announces Phase I SBIR Grant Award from the National Science Foundation

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

Manhattan BioSolutions Signs an Option to Exclusive License Agreement with the University at Buffalo to Develop Novel Monoclonal Antibody Targeting a Multiligand Receptor Involved in Inflammatory Responses and Cancer

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Manhattan BioSolutions secures non-dilutive angel funding

Scientific Platforms

Biologics

Developing novel biologics – mAbs & ADCs that target immuno-regulatory receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated mechanisms

Synthetic Microbes

The sMIST (Synthetic Microbial Immune Stimulators) platform is based on genetically engineered microbes – “living drugs” that target mutated tumor antigens to induce innate and tumor-specific adaptive immunity

Get in touch !

If you are interested in exploring innate immunity and its translation into human therapies, or if your technology could advance the science, please contact us at ir@manhattanbiosolutions.com